Antibacterial Therapy of Tularemia: Current Status and Prospects
- 7 June 2020
- journal article
- Published by Publishing House OKI in Antibiotics and Chemotherapy
- Vol. 65 (3-4), 39-44
- https://doi.org/10.37489/0235-2990-2020-65-3-4-39-44
Abstract
Антибактериальная терапия туляремии: современное состояние и перспективыThis publication has 34 references indexed in Scilit:
- Francisella Is Sensitive to Insect Antimicrobial PeptidesJournal of Innate Immunity, 2012
- Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemiaMedical Science Monitor, 2011
- Bioavailability and Efficacy of Levofloxacin against Francisella tularensis in the Common Marmoset ( Callithrix jacchus )Antimicrobial Agents and Chemotherapy, 2010
- Aktionsplan für TransplantationsmedizinDer Klinikarzt, 2010
- Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemiaJournal of Antimicrobial Chemotherapy, 2009
- Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibodyVaccine, 2008
- Tularaemia: bioterrorism defence renews interest in Francisella tularensisNature Reviews Microbiology, 2004
- TularemiaClinical Microbiology Reviews, 2002
- Bioterrorism: Implications for the Clinical MicrobiologistClinical Microbiology Reviews, 2001
- Reduced Virulence Of Rifampicin-Resistant Mutants Of Francisella Tularensis [X]The Journal of Infectious Diseases, 1994